ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2048

DDR2 auto-phosphorylation in patients with Warburg-Cinotti syndrome promotes differentiation of fibroblasts into myofibroblasts and expansion of immature B cells with antibody production.
Abstract Number: 2049

Descriptive Analysis of a Cohort of Neurosarcoidosis Mimics
Abstract Number: 2050

Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis
Abstract Number: 2051

Clinical Burden of Illness Among Patients with Immunoglobulin-G4-Related Disease in the United States
Abstract Number: 2052

Prevalence of anti-neutrophil extracellular trap antibodies and their relationship with the clinical characteristics of patients with idiopathic inflammatory myopathies.
Abstract Number: 2053

A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
Abstract Number: 2054

A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort
Abstract Number: 2055

Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis
Abstract Number: 2056

Systematic Review: Nutritional Interventions in Muscle Diseases
Abstract Number: 2057

Clinical Associations of Anti-Ro52 Antibodies in Idiopathic Inflammatory Myopathies: A Scoping Review
Abstract Number: 2058

Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort
Abstract Number: 2059

Autoantibody Patterns in Myositis Immunoblot Testing: A Retrospective Study inInflammatory Myopathies and Connective Tissue Diseases (2017–2023)
Abstract Number: 2060

Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
Abstract Number: 2061

Tryptophan Metabolism Alteration Is Associated With Rapidly Progressive Interstitial Lung Disease Of Anti-MDA5+ Dermatomyositis
Abstract Number: 2062

Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].